M. Cork, “Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study”, J of Skin, vol. 4, no. 6, p. s104, Oct. 2020.